&nbsp;

Dec 2022

Drug

letrozole

Other Name(s): Femara®

Quick Link(s):

May 2022

Drug

lapatinib

Other Name(s): Tykerb®

Quick Link(s):

Dec 2022

Drug

PERTuzumab

Other Name(s): Perjeta®

Quick Link(s):

Sep 2022

Regimen

LENA

Cancer Type:

Hematologic,

Myelodysplastic Syndrome (MDS)

Intent: Palliative

Funding:

ODB Limited Use

lenalidomide - For the treatment of patients with anemia due to myelodysplastic syndrome (MDS), according to clinical criteria

Drugs Used:

lenalidomide

Quick Link(s):

Regimen Monograph

May 2022

Regimen

PACL+PERT+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2022

Regimen

PACL(W)+TRAS

Cancer Type:

Breast

Intent: Adjuvant

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer

Drugs Used:

PACLitaxel,

trastuzumab

Quick Link(s):

Regimen Monograph

Feb 2022

Regimen

PACL(W)+PERT+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2022

Regimen

LENA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB Limited Use

lenalidomide - For the maintenance treatment of patients with newly diagnosed multiple myeloma, following ASCT, according to clinical criteria

Drugs Used:

lenalidomide

Quick Link(s):

Regimen Monograph

May 2022

Regimen

PERT+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

Drugs Used:

PERTuzumab,

trastuzumab

Quick Link(s):

Regimen Monograph

Sep 2022

Regimen

LENA

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade

Intent: Palliative

Drugs Used:

lenalidomide (Unfunded)

Quick Link(s):

Regimen Monograph

May 2022

Regimen

LENA(MNT)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade

Intent: Curative

Drugs Used:

lenalidomide (Unfunded)